PURE Bioscience, Inc. (OTCMKTS:PURE) Sees Significant Decline in Short Interest

Posted by on Aug 13th, 2023

PURE Bioscience, Inc. (OTCMKTS:PURE – Get Free Report) was the target of a large decline in short interest during the month of July. As of July 31st, there was short interest totalling 3,600 shares, a decline of 25.0% from the July 15th total of 4,800 shares. Based on an average daily volume of 8,400 shares, the days-to-cover ratio is presently 0.4 days.

PURE Bioscience Stock Performance

PURE Bioscience stock opened at $0.11 on Friday. PURE Bioscience has a fifty-two week low of $0.07 and a fifty-two week high of $0.24. The company has a market cap of $11.91 million, a PE ratio of -2.66 and a beta of 0.13. The business’s 50-day simple moving average is $0.10 and its two-hundred day simple moving average is $0.12.

PURE Bioscience (OTCMKTS:PURE – Get Free Report) last released its quarterly earnings results on Wednesday, June 14th. The company reported ($0.01) earnings per share for the quarter. The business had revenue of $0.41 million during the quarter. PURE Bioscience had a negative return on equity of 151.03% and a negative net margin of 247.89%.

PURE Bioscience Company Profile

(Get Free Report)

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.

Featured Stories

Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.